TNF Inhibitors in Psoriasis: A Review

Francisco A Kerdel BSc Mbbs

doi:10.12788/j.sder.2015.0137

TNF Inhibitors in Psoriasis: A Review

Semin Cutan Med Surg. 2015 Mar;34(2 Suppl):S37-9. doi: 10.12788/j.sder.2015.0137.

Author

Francisco A Kerdel BSc Mbbs¹

Affiliation

¹ University of Miami Hospital Professor of Dermatology and Vice Chairman, Florida International University, Miami, Florida.

PMID: 26625254
DOI: 10.12788/j.sder.2015.0137

Abstract

Adalimumab, etanercept, and infliximab are tumor necrosis factor (TNF) inhibitors that are currently approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. The availability of these biologic agents established a new benchmark in the treatment of psoriasis that requires systemic therapy to control psoriasis signs and symptoms. Although a number of other biologic agents and small molecules have been approved recently, TNF inhibitors remain a cornerstone of psoriasis therapy. Semin Cutan Med Surg 34(supp2):S37-S39 © 2015 published by Frontline Medical Communications.

Keywords: Adalimumab; etanercept; immunogenicity; infliximab; interleukin-23 inhibitors; psoriasis; tumor necrosis factor inhibitors.

2015 published by Frontline Medical Communications.